Skip to main content
Contact Us
Subscribe
E-Edition
40°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xeris Pharmaceuticals Inc
(NQ:
XERS
)
2.210
+0.170 (+8.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xeris Pharmaceuticals Inc
< Previous
1
2
3
Next >
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
March 06, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
March 06, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
February 28, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
February 05, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
January 10, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 05, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Updates Its Outlook for 2023
January 04, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023
October 16, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces Private Convertible Note Exchange Transactions
September 27, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate in the 2023 Cantor Global Healthcare Conference
September 14, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
August 08, 2023
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the...
Via
Newsfile
Xeris Biopharma Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023
August 01, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Ships One Millionth Gvoke® Unit
July 31, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism
June 21, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Participate at the Jefferies Healthcare Conference
June 01, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports First Quarter 2023 Financial Results
May 09, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023
May 02, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations
April 18, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™
March 30, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Appoints Ricki Fairley to Board of Directors
March 29, 2023
From
Xeris Biopharma Holdings
Via
Business Wire
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
March 08, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023
February 23, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023
February 02, 2023
From
Xeris Biopharma, Inc.
Via
Business Wire
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®
January 30, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Updates Its Outlook For 2022
January 05, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.